The DOI matches its Crossref record; 403 of the 403 references it cites were found in a registry or an index.
Frontiers in the treatment of glioblastoma: Past, present and emerging
Abstract
Glioblastoma (GBM) is one of the most aggressive cancers of the brain. Despite extensive research over the last several decades, the survival rates for GBM have not improved and prognosis remains poor. To date, only a few therapies are approved for the treatment of GBM with the main reasons being: 1) significant tumour heterogeneity which promotes the selection of resistant subpopulations 2) GBM induced immunosuppression and 3) fortified location of the tumour in the brain which hinders the delivery of therapeutics. Existing therapies for GBM such as radiotherapy, surgery and chemotherapy have been unable to reach the clinical efficacy necessary to prolong patient survival more than a few months. This comprehensive review evaluates the current and emerging therapies including those in clinical trials that may potentially improve both targeted delivery of therapeutics directly to the tumour site and the development of agents that may specifically target GBM. Particular focus has also been given to emerging delivery technologies such as focused ultrasound, cellular delivery systems nanomedicines and immunotherapy. Finally, we discuss the importance of developing novel materials for improved delivery efficacy of nanoparticles and therapeutics to reduce the suffering of GBM patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Moghaddam, S. P. H., Mohammadpour, R., & Ghandehari, H. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.08.028 · Cited by 120
RetractedAn MSN-PEG-IP drug delivery system and IL13Rα2 as targeted therapy for glioma
Shi, J., Hou, S., Huang, J., Wang, S., Wei, H. J., Huang, C., Liu, X., Jiang, R., Qian, W., Lu, J., et al. (2017) · Nanoscale · doi:10.1039/c6nr08786h · Cited by 38
RetractedRadiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
Ostrom, Q. T., Gittleman, H., Farah, P., Ondracek, A., Chen, Y., Wolinsky, Y., Stroup, N. E., Kruchko, C., & Barnholtz-Sloan, J. S. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not151 · Cited by 11,994
Introduction to Metal–Organic Frameworks
Zhou, H.-C., Long, J. R., & Yaghi, O. M. (2012) · Chemical Reviews · doi:10.1021/cr300014x · Cited by 7,720
Stupp, R., Hegi, M. E., Mason, W. P., van den Bent, M. J., Taphoorn, M. J., Janzer, R. C., Ludwin, S. K., Allgeier, A., Fisher, B., Belanger, K., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70025-7 · Cited by 7,668
Analysis of nanoparticle delivery to tumours
Wilhelm, S., Tavares, A. J., Dai, Q., Ohta, S., Audet, J., Dvorak, H. F., & Chan, W. C. W. (2016) · Nature Reviews Materials · doi:10.1038/natrevmats.2016.14 · Cited by 5,218
Monocyte and macrophage heterogeneity
Gordon, S., & Taylor, P. R. (2005) · Nature Reviews Immunology · doi:10.1038/nri1733 · Cited by 5,190
PEGylation as a strategy for improving nanoparticle-based drug and gene delivery
Suk, J. S., Xu, Q., Kim, N., Hanes, J., & Ensign, L. M. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.09.012 · Cited by 4,523
Ultrahigh Porosity in Metal-Organic Frameworks
Furukawa, H., Ko, N., Go, Y. B., Aratani, N., Choi, S. B., Choi, E., Yazaydin, A. Ö., Snurr, R. Q., O’Keeffe, M., Kim, J., et al. (2010) · Science · doi:10.1126/science.1192160 · Cited by 3,904
Cited by
Chen, C., Jing, W., Chen, Y., Wang, G., Abdalla, M., Gao, L., Han, M., Shi, C., Li, A., Sun, P., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abn1128 · Cited by 291
Janjua, T. I., Cao, Y., Kleitz, F., Linden, M., Yu, C., & Popat, A. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.115115 · Cited by 259
Self-citationLiu, X., Cao, Z., Wang, W., Zou, C., Wang, Y., Pan, L., Jia, B., Zhang, K., Zhang, W., Li, W., et al. (2023) · ACS Nano · doi:10.1021/acsnano.2c12857 · Cited by 132
Long Non-coding RNA KTN1-AS1 Targets miR-505 to Promote Glioblastoma Progression
Guo, K., Fang, L., Li, M., Li, A., & Liu, N. (2023) · Behavioural Neurology · doi:10.1155/2023/4190849 · Cited by 6
Metadata
- Authors
- Janjua, T. I., Rewatkar, P., Ahmed-Cox, A., Saeed, I., Mansfeld, F. M., Kulshreshtha, R., Kumeria, T., Ziegler, D. S., Kavallaris, M., Mazzieri, R., & Popat, A.
- Venue
- Advanced Drug Delivery Reviews
- Publisher
- Elsevier BV
- Published
- 2021-04
- Volume
- 171
- Pages
- 108-138
- ISSN
- 0169-409X (ISSN-L)
- OpenAlex
- W3124899091
- Cited by
- 257
- References
- 403
- FWCI
- 12.56
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Frontiers in the treatment of glioblastoma: Past, present and emerging. https://app.cochat.ai/papers/10.1016/j.addr.2021.01.012
- The paper
- Janjua, T. I., Rewatkar, P., Ahmed-Cox, A., Saeed, I., Mansfeld, F. M., Kulshreshtha, R., Kumeria, T., Ziegler, D. S., Kavallaris, M., Mazzieri, R., & Popat, A. (2021). Frontiers in the treatment of glioblastoma: Past, present and emerging. Advanced Drug Delivery Reviews. https://doi.org/10.1016/j.addr.2021.01.012
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
